Clinically important differences in the pharmacokinetics of the ten newer "atypical" antipsychotics: Part 1

Journal of Psychiatric Practice

Volumn 18, Issue 3, 2012, Pages 199-204

  Preskorn, Sheldon H ^a,b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

atypical antipsychotics; bioavailability; cytochrome P450 enzymes; half life; pharmacokinetics

Indexed keywords

ARIPIPRAZOLE; ASENAPINE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; FLUVOXAMINE; ILOPERIDONE; KETOCONAZOLE; LURASIDONE; OLANZAPINE; PALIPERIDONE; PAROXETINE; QUETIAPINE; QUINIDINE; RISPERIDONE; VALPROATE SEMISODIUM; ZIPRASIDONE;

AREA UNDER THE CURVE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TRANSFORMATION; FOOD DRUG INTERACTION; HUMAN; MAXIMUM PLASMA CONCENTRATION; REVIEW;

ANTIPSYCHOTIC AGENTS; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; HALF-LIFE; HUMANS;

EID: 84861894873     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pra.0000415076.28497.8e     Document Type: Review

References (17)

1. Preskorn SH. The evolution of antipsychotic drug therapy; Reserpine, chlorpromazine, and haloperidol. J Psychiatr Pract 2007;13:253-60.
2. Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 1989;251:238-46.
3. Meltzer HY, Matsubara S, Lee JC. The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 1989;25:390-2.
4. Tadori Y, Forbes RA, McQuade RD, et al. In vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors. Eur J Pharmacol 2011;668:355-65.
5. Preskorn SH. Drugs are an acquired source of biological variance among patients. J Psychiatr Pract 2006;12:391-6.
6. Abilify (aripiprazole) prescribing information, February 2012, Bristo-Meyers Squibb and Otsuka Pharmaceutical (available at www.abilify.com, accessed May 4, 2012).
7. Saphris (asenapine) prescribing information, October 2011, Merck and Company (available at hcp.saphris.com/asenapine/saphris/hcp/default.jsp, accessed May 4, 2012).
8. Clozaril (clozapine) prescribing information, October 2011, Novartis Pharmaceuticals (available at www.pharma.us.novartis.com/product/pi/pdf/ Clozaril.pdf, accessed May 4, 2012).
9. Fanapt (iloperidone) prescribing information, January 2012, Novartis Pharmaceuticals (available at www.phar-ma.us.novartis.com/product/pi/pdf/fanapt. pdf, accessed May 4, 2012).
10. Latuda [lurasidone] prescribing information, April 2012, Sunovion Pharmaceuticals (available at www.latuda.com/LatudaPrescribingInformation.pdf, accessed May 3, 2012).
11. Zyprexa (olanzapine) prescribing information, June 2011, Eli Lilly (available at pi.lilly.com/us/zyprexa-pi.pdf, accessed May 4, 2012).
12. Invega (paliperidone) prescribing information, September 2011, Janssen Pharmaceuticals (available at www.invega-sustenna.com/important-product- information, accessed May 4, 2012).
13. Seroquel (quetiapine) prescribing information, February 2012, AstraZeneca Pharmaceuticals (available at www.astrazeneca-us.com/pi/Seroquel.pdf, accessed May 4, 2012).
14. Risperdol (risperidone) prescribing information, Septem ber 2011, Janssen Pharmaceuticals (available at www.risperdal.com/prescribing.html, accessed May 4, 2012).
15. Geodon (ziprasidone) prescribing information, December 2010, Pfizer (available at labeling.pfizer.com/Show-Labeling.aspx?id=584, accessed May 4, 2012).
16. DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: An atypical antipsychotic. Clin Pharmacokinet 2001;40:509-22.
17. Lincoln J, Stewart ME, Preskorn SH. How sequential studies inform drug development: Evaluating the effect of food intake on optimal bioavailability of ziprasidone. J Psychiatr Pract 2010;16:103-14.